AGF Investments Inc. lifted its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 46.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,418,995 shares of the company’s stock after purchasing an additional 449,936 shares during the period. AGF Investments Inc. owned approximately 0.14% of Teva Pharmaceutical Industries worth $30,565,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. PointState Capital LP bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth approximately $161,826,000. Renaissance Technologies LLC raised its stake in shares of Teva Pharmaceutical Industries by 348.1% during the second quarter. Renaissance Technologies LLC now owns 4,036,863 shares of the company’s stock worth $98,177,000 after buying an additional 3,135,900 shares during the last quarter. Thornburg Investment Management Inc. raised its stake in shares of Teva Pharmaceutical Industries by 5.3% during the third quarter. Thornburg Investment Management Inc. now owns 4,028,192 shares of the company’s stock worth $86,767,000 after buying an additional 202,777 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth approximately $90,746,000. Finally, Swiss National Bank raised its stake in shares of Teva Pharmaceutical Industries by 8.8% during the second quarter. Swiss National Bank now owns 3,686,899 shares of the company’s stock worth $89,665,000 after buying an additional 298,600 shares during the last quarter. Institutional investors own 65.37% of the company’s stock.

Shares of NYSE:TEVA opened at $23.53 on Wednesday. Teva Pharmaceutical Industries Ltd has a 52 week low of $11.49 and a 52 week high of $25.96. The company has a quick ratio of 0.61, a current ratio of 0.94 and a debt-to-equity ratio of 1.75. The company has a market capitalization of $23.85 billion, a price-to-earnings ratio of 5.99, a PEG ratio of 7.14 and a beta of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, November 1st. The company reported $0.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The firm had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.54 billion. During the same quarter in the prior year, the firm earned $1.00 earnings per share. The business’s quarterly revenue was down 19.4% on a year-over-year basis. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.8 EPS for the current year.

In other news, VP Richard Daniell sold 2,488 shares of the stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $23.69, for a total transaction of $58,940.72. Following the completion of the sale, the vice president now owns 2,488 shares of the company’s stock, valued at $58,940.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Deborah A. Griffin sold 2,376 shares of the stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total transaction of $56,334.96. Following the sale, the insider now directly owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The disclosure for this sale can be found here. Insiders sold 6,531 shares of company stock valued at $152,749 in the last ninety days. Insiders own 0.43% of the company’s stock.

A number of research firms recently weighed in on TEVA. Cantor Fitzgerald reissued a “hold” rating and set a $25.00 price target on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 16th. Royal Bank of Canada reissued a “hold” rating and set a $19.00 price target on shares of Teva Pharmaceutical Industries in a research note on Tuesday, July 31st. Oppenheimer reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 2nd. Morgan Stanley boosted their price target on shares of Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Friday, August 3rd. Finally, Credit Suisse Group set a $26.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Monday, September 17th. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and a consensus price target of $22.08.

ILLEGAL ACTIVITY NOTICE: This story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/11/14/agf-investments-inc-increases-stake-in-teva-pharmaceutical-industries-ltd-teva.html.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: What is Cost of Capital?

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.